Rajgopal Govindarajan
Associate Professor
Pharmaceutics and Pharmaceutical Chemistry
544 Riffe Building


  • Pancreatic cancer developmental therapeutics
  • Nucleoside and oligonucleotide based therapeutics
  • Nucleoside drug transporters
  • MicroRNAs in cancer

Professional Interests

Dr. Govindarajan’s laboratory is interested in understanding and overcoming drug resistance in pancreatic cancer. His training is in the areas of animal sciences, cancer biology and drug transport-based pharmacokinetics, and has extensively used cell and animal models to evaluate nucleoside and oligonucleotide therapies. He also developed several new insights into the pharmacology and cytotoxicity of nucleoside analog drugs. Current focuses in his laboratory are to understand the epigenetic alterations in pancreatic cancer and to evaluate novel epigenetic reversal agents for effective pancreatic cancer treatment. Understanding epigenetic regulation of pluripotent stem cell factors in microRNA biogenesis is also of interest.


  • Postdoc - University of Washington, Seattle, WA
  • PhD - University of Nebraska Medical Center, Omaha, NE
  • MVSc - Indian Veterinary Research Institute, India
  • BVSc - Madras Veterinary College, TANUVAS, India


  • 2015: American Cancer Society Research Scholar
  • 2015: Presented Elkin Lecture, Emory Winship Cancer Institute
  • 2015: Reviewer, NIH Developmental Therapeutics (DT) Study Section
  • 2013: Reviewer, NIH ZRG1 OTC-X AREA: Oncological Sciences Study Section
  • 2012: NIH Academic Research Enhancement Award
  • 2012: Cancer Research Award , Georgia Cancer Coalition & Georgia Research Alliance
  • 2011: Randy Ellison Cancer Research Award, College of Pharmacy, University of Georgia
  • 2010: Developmental Research Project (DRP) SPORE Awardee, Emory Winship Cancer Institute
  • 2009: Developmental Research Project (DRP) SPORE Awardee, Emory Winship Cancer Institute

Recent Publications